These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26810815)

  • 1. National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.
    Malayeri AA; Brooks KM; Bryant LH; Evers R; Kumar P; Reich DS; Bluemke DA
    J Am Coll Radiol; 2016 Mar; 13(3):237-41. PubMed ID: 26810815
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
    Runge VM
    Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium Deposition after Contrast-enhanced MR Imaging.
    Kanda T; Matsuda M; Oba H; Toyoda K; Furui S
    Radiology; 2015 Dec; 277(3):924-5. PubMed ID: 26599932
    [No Abstract]   [Full Text] [Related]  

  • 4. Intracranial Deposition of Intravenous Gadolinium Contrast: A Literature Review.
    Franco J
    Radiol Technol; 2017 Mar; 88(4):435-439. PubMed ID: 28298504
    [No Abstract]   [Full Text] [Related]  

  • 5. Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo?
    Huckle JE; Altun E; Jay M; Semelka RC
    Invest Radiol; 2016 Apr; 51(4):236-40. PubMed ID: 26588463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium Deposition and Chronic Toxicity.
    Ramalho J; Ramalho M
    Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):765-778. PubMed ID: 28964466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America.
    Mithal LB; Patel PS; Mithal D; Palac HL; Rozenfeld MN
    Pediatr Radiol; 2017 May; 47(6):657-664. PubMed ID: 28283727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and chemical forms of gadolinium in the brain: a review.
    Kanda T; Nakai Y; Hagiwara A; Oba H; Toyoda K; Furui S
    Br J Radiol; 2017 Nov; 90(1079):20170115. PubMed ID: 28749164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium depositions after the application of the hepatospecific gadolinium-based contrast agent gadoxetate disodium.
    Kim SY; Maurer MH; Richter JK; Heverhagen JT; Boehm IB
    Eur J Intern Med; 2018 Jan; 47():e9-e11. PubMed ID: 28965739
    [No Abstract]   [Full Text] [Related]  

  • 10. Response.
    McDonald RJ; McDonald JS; Kallmes DF; Jentoft ME; Murray DL; Thielen KR; Williamson EE; Eckel LJ
    Radiology; 2015 Dec; 277(3):925. PubMed ID: 26929976
    [No Abstract]   [Full Text] [Related]  

  • 11. Gadolinium retention - 5 years later….
    Dillman JR; Davenport MS
    Pediatr Radiol; 2020 Feb; 50(2):166-167. PubMed ID: 31975183
    [No Abstract]   [Full Text] [Related]  

  • 12. Gadolinium deposition in the brain: summary of evidence and recommendations.
    Gulani V; Calamante F; Shellock FG; Kanal E; Reeder SB;
    Lancet Neurol; 2017 Jul; 16(7):564-570. PubMed ID: 28653648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus development summaries. Magnetic resonance imaging. National Institutes of Health.
    Conn Med; 1988 Mar; 52(3):153-9. PubMed ID: 3282772
    [No Abstract]   [Full Text] [Related]  

  • 14. Residual or retained gadolinium: practical implications for radiologists and our patients.
    Kanal E; Tweedle MF
    Radiology; 2015 Jun; 275(3):630-4. PubMed ID: 25942418
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus.
    Runge VM
    Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on brain MRI for the diagnosis and follow-up of MS patients.
    Brisset JC; Vukusic S; Cotton F;
    Presse Med; 2021 Jun; 50(2):104067. PubMed ID: 33989722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.
    Martí-Bonmatí L; Martí-Bonmatí E
    Radiologia; 2017; 59(6):469-477. PubMed ID: 29110904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
    Murata N; Gonzalez-Cuyar LF; Murata K; Fligner C; Dills R; Hippe D; Maravilla KR
    Invest Radiol; 2016 Jul; 51(7):447-53. PubMed ID: 26863577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium Retention and Toxicity-An Update.
    Ramalho M; Ramalho J; Burke LM; Semelka RC
    Adv Chronic Kidney Dis; 2017 May; 24(3):138-146. PubMed ID: 28501075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.
    McDonald RJ; McDonald JS; Kallmes DF; Jentoft ME; Murray DL; Thielen KR; Williamson EE; Eckel LJ
    Radiology; 2015 Jun; 275(3):772-82. PubMed ID: 25742194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.